KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Net Cash Flow (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Net Cash Flow for 7 consecutive years, with -$320.2 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 1423.1% to -$320.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$310.3 million through Dec 2025, down 168.65% year-over-year, with the annual reading at -$310.3 million for FY2025, 168.65% down from the prior year.
  • Net Cash Flow hit -$320.2 million in Q4 2025 for Royalty Pharma, down from $307.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $921.6 million in Q2 2024 to a low of -$1.2 billion in Q3 2023.
  • Historically, Net Cash Flow has averaged -$19.5 million across 5 years, with a median of $178.0 million in 2023.
  • Biggest five-year swings in Net Cash Flow: surged 376.84% in 2022 and later plummeted 1423.1% in 2025.
  • Year by year, Net Cash Flow stood at -$259.8 million in 2021, then soared by 376.84% to $719.1 million in 2022, then crashed by 163.89% to -$459.4 million in 2023, then surged by 95.42% to -$21.0 million in 2024, then tumbled by 1423.1% to -$320.2 million in 2025.
  • Business Quant data shows Net Cash Flow for RPRX at -$320.2 million in Q4 2025, $307.0 million in Q3 2025, and -$455.8 million in Q2 2025.